WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE PROCESS OF CARE IN CAP?
4. WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE PROCESS OF CARE IN CAP?
Process of care measures may be more pragmatic endpoints than “tradi- tional” outcomes (e.g., mortality) in CAP research or QI. Process measures, however, should be linked to clinical, patient-centred, or economic outcomes. This section will review the evidence that QI interventions improve process of care in CAP.
4.1. Aspects of process that are likely to impact on clinical and patient-centred outcomes
In a cleverly designed controlled before–after study, Chu et al. (2003) showed that feedback from an external QI agent resulted in a higher proportion of patients receiving antibiotics within 4 hr of admission at intervention com- pared to control hospitals (69% vs 57%). This change appears to have been mediated through the use of either clinical pathways or standing orders. When control hospitals were subsequently exposed to the intervention, delivery of antibiotics at these sites also improved (66% vs 53%). This evidence is sup- ported by three uncontrolled studies. Benenson et al. (1999) used a before– after study with the use of two post-implementation cohorts to evaluate the impact of a care pathway that emphasised the importance of the early diagno- sis and delivery of antibiotic therapy. Door to antibiotic time decreased from 315 to 175 min and 171 min at 1 and 3 years post-implementation, respec- tively. Although uncontrolled, this is an interesting finding as there has been concern about the sustainability of QI interventions. Meehan et al. (2001) found that a locally customised statewide care pathway improved the delivery of antibiotics within 8 hr of admission to hospital from 83% to 89%. Lawrence et al. (2002) used an educational intervention with monthly audit and feedback to reduce door to antibiotic time from 413 to 291 min. In some of these studies (Chu et al., 2003; Lawrence et al., 2002), sputum and blood culture procure- ment have also increased. As discussed above, however, it is debatable if these processes of care have an impact on outcomes.
Pneumonia Guidelines in Practice
49 In another uncontrolled study, Suchyta et al. (2001) used a practice guide-
line incorporating the American Thoracic Society’s (ATS’s) antibiotic guidance to increase the use of recommended antibiotics from 45% to 72%. Using a wide range of interventions and in the largest published controlled CAP QI study to date; Dean et al. showed an improvement in overall use of guideline antibi- otics in study hospitals from 28% to 56% (Dean et al., 2001). In the only UK study, Al-Eidan et al. (2000) described a reduction in the diversity of antibiotics used in CAP (from 12 to 3) following implementation of a practice guideline.
4.2. Aspects of process that are likely to impact on economic outcomes
In an uncontrolled before–after study, Atlas et al. (1998) found that the use of the PSI as admission decision support, increased low-risk patients managed as outpatients from 42% to 57%. The intervention included a study nurse during weekday working hours, enhanced outpatient services, and the use of oral clari- thromycin. These findings were subsequently confirmed in the only randomised CAP QI trial. A care pathway, which incorporated the PSI with levofloxacin, reduced the proportion of low-risk patients admitted to hospital from 49% to 31% without impacting on patients’ quality of life or clinical outcomes (Marrie et al., 2000). Using an adapted version of the ATS admission guidance, Suchyta et al. (2001) also safely reduced hospital admission from 14% to 6%.
An early switch from IV to oral therapy and subsequent discharge from hospital has been shown to be a safe and cost-effective strategy for CAP in randomised controlled trials (Castro-Guardiola et al., 2001; Paladino et al., 2002). Only a few studies have evaluated this strategy, however, as part of a QI intervention. Al-Eidan et al. (2000) demonstrated a reduction in IV antibiotic administration from 6 to 2 mean days. In contrast, Rhew et al. (1998) were unable to demonstrate a significant change in guideline adherence following the implementation of physician decision support for this aspect of care. This study was underpowered, however, to detect clinically important changes. In another small study (not shown in the tables), Weingarten et al. (1996) found similar results.
Parts
» Antibiotic Policies: Theory and Practice
» THEORIES OF FACILITATING CHANGE
» OTHER APPROACHES TO GUIDELINE DEVELOPMENT
» QUALITY ASSURANCE AND DEVELOPMENT OF STANDARDS
» DEVELOPMENT OF CLINICAL STANDARDS IN SCOTLAND
» WHICH QI INTERVENTIONS HAVE BEEN STUDIED IN CAP?
» LINKING PROCESS OF CARE TO OUTCOMES IN QI
» WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE PROCESS OF CARE IN CAP?
» WHAT IS THE EVIDENCE THAT QI INITIATIVES IMPROVE OUTCOMES IN CAP?
» Designing and implementing a CAP intervention
» LEVEL OF AGGREGATION OF ANTIMICROBIALS
» ANTIMICROBIAL USAGE MEASURES
» Relationships based on patient-specific data
» Relationships based on aggregate usage
» ANTIBIOTIC CONSUMPTION; ALTERNATIVE UNITS OF MEASUREMENT
» ANTIBIOTIC CONSUMPTION CALCULATOR
» BENCHMARKING FOR REDUCING VANCOMYCIN USE AND VANCOMYCIN- RESISTANT ENTEROCOCCI IN US ICU S
» THE HARVARD EMERGENCY DEPARTMENT QUALITY STUDY
» ANALYSIS BY INDIVIDUAL ANTIMICROBIAL AGENT
» BENCHMARKING WITH OTHER ANTIMICROBIAL UTILISATION DATA
» STATE OF THE ART OF ANTIBIOTIC PROPHYLAXIS IN SURGERY
» AUDITING AND IMPROVING THE QUALITY OF ANTIBIOTIC PROPHYLAXIS IN SURGERY
» TYPES OF STUDIES TO OBTAIN QUALITY DATA ON A PATIENT LEVEL
» MULTIDISCIPLINARY ANTIMICROBIAL MANAGEMENT TEAMS
» THE ROLE OF THE PHARMACIST IN INFECTION MANAGEMENT
» TRAINING AND SUPPORT IN INFECTION MANAGEMENT FOR PHARMACISTS
» ANTIBIOTIC POLICY IN THE TERTIARY CARE CENTRE
» ANTIBIOTIC CONSUMPTION IN ICU S
» ANTIBIOTIC RESISTANCE IN ICU
» The impact of antibiotic policies and antibiotic consumption on antibiotic resistance
» IT and benchmarking to improve antibiotic prescribing
» COST OF HOSPITAL-ACQUIRED INFECTION
» THE COST OF ANTIMICROBIAL RESISTANCE
» Costs of screening/surveillance cultures
» Isolation, cohorting, and contact isolation
» EPIDEMIOLOGY OF INVASIVE FUNGAL INFECTIONS
» Antifungal resistance in Candida species
» Antifungal resistance cannot be transmitted by extrachromosomal DNA
» RATIONAL USE OF ANTIFUNGAL AGENTS
» THE CHANGING FACE OF VIRAL INFECTIONS AND THEIR MANAGEMENT
» PROBLEMS ASSOCIATED WITH ANTIVIRAL THERAPY
» ANTIVIRAL TREATMENT STRATEGIES
» ANTIVIRAL PROPHYLAXIS STRATEGIES
» ANTIBIOTIC CONCENTRATIONS AT TARGET SITES
» An infant with aplastic anaemia
» A long-standing E. coli infection of liver cysts
» BREAKPOINTS: A SHORT HISTORY AND OVERVIEW
» PHARMACODYNAMIC RELATIONSHIPS AND EMERGENCE OF RESISTANCE
» EVALUATION OF THE ANTIMICROBIAL RESISTANCE SURVEILLANCE DATA PUBLISHED IN THE MEDICAL LITERATURE
» PRACTICAL ASPECTS OF THE IMPLEMENTATION OF THE SURVEILLANCE PROGRAM
» Multivariate analysis methods
» Evolutionary genetic approaches
» Study of the relationship between bacterial resistance and antimicrobial consumption
» To predict the short-term evolution of resistance
» To evaluate interventions to control antibiotic resistance
» DISINFECTANTS: TYPES, ACTIONS, AND USAGES
» Evidence of bacterial resistance to biocides
» Mechanisms of bacterial resistance to biocides
» EVIDENCE OF CROSS-RESISTANCE BETWEEN BIOCIDES AND ANTIBIOTICS
» DISINFECTANT USAGE AND ANTIBIOTIC RESISTANCE
» METHODS OF LITERATURE REVIEW
» PROBLEMS WITH INTERPRETATION OF PUBLISHED STUDIES
» Distribution of educational materials
» Audit and feedback with or without other educational materials
» Educational group meetings or seminars
» Educational outreach/academic detailing
» Financial/healthcare system changes
» EFFECT OF INTERVENTIONS ON ANTIBIOTIC RESISTANCE
» DDD/1,000 INHABITANTS AND DAY (DID)
» PRESCRIPTIONS/1,000 INHABITANTS AND YEAR
» INDICATIONS FOR ANTIBIOTIC PRESCRIPTIONS
» POSSIBLE CAUSES FOR OBSERVED VARIATIONS IN ANTIBIOTIC USE
» DETERMINANTS OF ANTIBIOTIC CONSUMPTION
» COLLECTIVE AWAKENING AND PROGRESSIVE MOBILIZATION OF FRENCH PUBLIC HEALTH AUTHORITIES
» ANTIBIOTIC USE AND COST TRENDS
» IMPACT ON HEALTH BUDGETS OF ANTIBIOTIC USE
» ACCESS TO ESSENTIAL ANTIBIOTICS AT ALL LEVELS OF CARE
» EPIDEMIOLOGY OF ANTIMICROBIAL RESISTANCE
» THREAT OF ANTIMICROBIAL RESISTANCE
» ECONOMIC IMPLICATIONS OF ANTIMICROBIAL RESISTANCE
» FACTORS CONTRIBUTING TO DEVELOPMENT AND SPREAD OF RESISTANCE
» STRATEGIES FOR CONTAINMENT OF RESISTANCE IN DEVELOPING COUNTRIES
» Antibacterial resistance and policies
» Policies, guidelines, and education on antibacterial use
» Discovery, development, and commercialization in the face of policies
» Antibacterial development, labelling, and benefits
» WHAT CAN BE DONE NOW ABOUT ANTIBIOTIC RESISTANCE?
» HOW CAN THE DIAGNOSTIC LABORATORY HELP?
Show more